Once-daily fixed combination of captopril and hydrochlorothiazide as first line therapy for mild to moderate hypertension

James Mersey, Pierre D'Hemecourt, Kenneth Blaze

Research output: Contribution to journalArticle

Abstract

The efficacy and safety of a single daily dose of captopril combined with hydrochlorothiazide were evaluated in a double-blind, placebo-controlled, randomized, multicenter, parallel-group study. Three-hundred forty-five patients with mild to moderate hypertension (seated diastolic blood pressure [DBP], 92 to 109 mmHg) were randomly assigned to receive placebo, 25 mg of captopril, 12.5 mg of hydrochlorothiazide, 25 mg of captopril plus 12.5 mg of hydrochlorothiazide, or 50 mg of captopril plus 25 mg of hydrochlorothiazide. After a 4- to 6-week single-blind placebo lead-in, patients took medication once daily for 8 weeks. Blood pressure was measured 24 ± 3 hours after the last drug dose. Both combination regimens reduced seated DBP more than placebo, captopril, or hydrochlorothiazide (P <0.05); the effects of the two combination regimens were similar. Neither 25 mg of captopril nor 12.5 mg of hydrochlorothiazide reduced seated DBP more than placebo. After 8 weeks, both combinations normalized seated DBP (≤90 mmHg) in approximately 60% of patients, which exceeded the 35% normalization rate in the placebo group (P <0.05). The frequency of clinical adverse events was similar (approximately 40%) in the placebo group and the two combination groups. It is concluded that both combinations of captopril and hydrochlorothiazide studied are suitable for once-daily treatment of mild to moderate hypertension, but the lower dose is preferred as initial therapy.

Original languageEnglish (US)
Pages (from-to)502-512
Number of pages11
JournalCurrent Therapeutic Research - Clinical and Experimental
Volume53
Issue number5
DOIs
StatePublished - 1993

Fingerprint

Blood Pressure
Hypertension
Hydrochlorothiazide
Captopril
Placebos
Therapeutics
hydrochlorothiazide drug combination captopril
Safety
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Once-daily fixed combination of captopril and hydrochlorothiazide as first line therapy for mild to moderate hypertension. / Mersey, James; D'Hemecourt, Pierre; Blaze, Kenneth.

In: Current Therapeutic Research - Clinical and Experimental, Vol. 53, No. 5, 1993, p. 502-512.

Research output: Contribution to journalArticle

@article{74aae77fd53b46a69c8e088aa5a30d44,
title = "Once-daily fixed combination of captopril and hydrochlorothiazide as first line therapy for mild to moderate hypertension",
abstract = "The efficacy and safety of a single daily dose of captopril combined with hydrochlorothiazide were evaluated in a double-blind, placebo-controlled, randomized, multicenter, parallel-group study. Three-hundred forty-five patients with mild to moderate hypertension (seated diastolic blood pressure [DBP], 92 to 109 mmHg) were randomly assigned to receive placebo, 25 mg of captopril, 12.5 mg of hydrochlorothiazide, 25 mg of captopril plus 12.5 mg of hydrochlorothiazide, or 50 mg of captopril plus 25 mg of hydrochlorothiazide. After a 4- to 6-week single-blind placebo lead-in, patients took medication once daily for 8 weeks. Blood pressure was measured 24 ± 3 hours after the last drug dose. Both combination regimens reduced seated DBP more than placebo, captopril, or hydrochlorothiazide (P <0.05); the effects of the two combination regimens were similar. Neither 25 mg of captopril nor 12.5 mg of hydrochlorothiazide reduced seated DBP more than placebo. After 8 weeks, both combinations normalized seated DBP (≤90 mmHg) in approximately 60{\%} of patients, which exceeded the 35{\%} normalization rate in the placebo group (P <0.05). The frequency of clinical adverse events was similar (approximately 40{\%}) in the placebo group and the two combination groups. It is concluded that both combinations of captopril and hydrochlorothiazide studied are suitable for once-daily treatment of mild to moderate hypertension, but the lower dose is preferred as initial therapy.",
author = "James Mersey and Pierre D'Hemecourt and Kenneth Blaze",
year = "1993",
doi = "10.1016/S0011-393X(05)80657-5",
language = "English (US)",
volume = "53",
pages = "502--512",
journal = "Current Therapeutic Research",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "5",

}

TY - JOUR

T1 - Once-daily fixed combination of captopril and hydrochlorothiazide as first line therapy for mild to moderate hypertension

AU - Mersey, James

AU - D'Hemecourt, Pierre

AU - Blaze, Kenneth

PY - 1993

Y1 - 1993

N2 - The efficacy and safety of a single daily dose of captopril combined with hydrochlorothiazide were evaluated in a double-blind, placebo-controlled, randomized, multicenter, parallel-group study. Three-hundred forty-five patients with mild to moderate hypertension (seated diastolic blood pressure [DBP], 92 to 109 mmHg) were randomly assigned to receive placebo, 25 mg of captopril, 12.5 mg of hydrochlorothiazide, 25 mg of captopril plus 12.5 mg of hydrochlorothiazide, or 50 mg of captopril plus 25 mg of hydrochlorothiazide. After a 4- to 6-week single-blind placebo lead-in, patients took medication once daily for 8 weeks. Blood pressure was measured 24 ± 3 hours after the last drug dose. Both combination regimens reduced seated DBP more than placebo, captopril, or hydrochlorothiazide (P <0.05); the effects of the two combination regimens were similar. Neither 25 mg of captopril nor 12.5 mg of hydrochlorothiazide reduced seated DBP more than placebo. After 8 weeks, both combinations normalized seated DBP (≤90 mmHg) in approximately 60% of patients, which exceeded the 35% normalization rate in the placebo group (P <0.05). The frequency of clinical adverse events was similar (approximately 40%) in the placebo group and the two combination groups. It is concluded that both combinations of captopril and hydrochlorothiazide studied are suitable for once-daily treatment of mild to moderate hypertension, but the lower dose is preferred as initial therapy.

AB - The efficacy and safety of a single daily dose of captopril combined with hydrochlorothiazide were evaluated in a double-blind, placebo-controlled, randomized, multicenter, parallel-group study. Three-hundred forty-five patients with mild to moderate hypertension (seated diastolic blood pressure [DBP], 92 to 109 mmHg) were randomly assigned to receive placebo, 25 mg of captopril, 12.5 mg of hydrochlorothiazide, 25 mg of captopril plus 12.5 mg of hydrochlorothiazide, or 50 mg of captopril plus 25 mg of hydrochlorothiazide. After a 4- to 6-week single-blind placebo lead-in, patients took medication once daily for 8 weeks. Blood pressure was measured 24 ± 3 hours after the last drug dose. Both combination regimens reduced seated DBP more than placebo, captopril, or hydrochlorothiazide (P <0.05); the effects of the two combination regimens were similar. Neither 25 mg of captopril nor 12.5 mg of hydrochlorothiazide reduced seated DBP more than placebo. After 8 weeks, both combinations normalized seated DBP (≤90 mmHg) in approximately 60% of patients, which exceeded the 35% normalization rate in the placebo group (P <0.05). The frequency of clinical adverse events was similar (approximately 40%) in the placebo group and the two combination groups. It is concluded that both combinations of captopril and hydrochlorothiazide studied are suitable for once-daily treatment of mild to moderate hypertension, but the lower dose is preferred as initial therapy.

UR - http://www.scopus.com/inward/record.url?scp=0027234816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027234816&partnerID=8YFLogxK

U2 - 10.1016/S0011-393X(05)80657-5

DO - 10.1016/S0011-393X(05)80657-5

M3 - Article

AN - SCOPUS:0027234816

VL - 53

SP - 502

EP - 512

JO - Current Therapeutic Research

JF - Current Therapeutic Research

SN - 0011-393X

IS - 5

ER -